nodes	percent_of_prediction	percent_of_DWPC	metapath
Bezafibrate—PPARG—psoriasis	0.413	1	CbGaD
Bezafibrate—CYP1A1—Clobetasol propionate—psoriasis	0.0867	0.202	CbGbCtD
Bezafibrate—CYP1A1—Methoxsalen—psoriasis	0.0456	0.106	CbGbCtD
Bezafibrate—CYP2C8—Tazarotene—psoriasis	0.0408	0.0952	CbGbCtD
Bezafibrate—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0357	0.0833	CbGbCtD
Bezafibrate—CYP1A1—Cholecalciferol—psoriasis	0.0302	0.0704	CbGbCtD
Bezafibrate—SLCO1B1—Cyclosporine—psoriasis	0.027	0.0631	CbGbCtD
Bezafibrate—CYP2C8—Cholecalciferol—psoriasis	0.0174	0.0406	CbGbCtD
Bezafibrate—CYP2C8—Mycophenolate mofetil—psoriasis	0.0151	0.0352	CbGbCtD
Bezafibrate—SLCO1B1—Methotrexate—psoriasis	0.0143	0.0334	CbGbCtD
Bezafibrate—CYP3A4—Calcitriol—psoriasis	0.0137	0.032	CbGbCtD
Bezafibrate—CYP1A1—Dexamethasone—psoriasis	0.0131	0.0305	CbGbCtD
Bezafibrate—CYP2C8—Hydrocortisone—psoriasis	0.0121	0.0283	CbGbCtD
Bezafibrate—CYP2C8—Cyclosporine—psoriasis	0.0114	0.0267	CbGbCtD
Bezafibrate—CYP3A4—Methoxsalen—psoriasis	0.0107	0.0249	CbGbCtD
Bezafibrate—CYP2C8—Dexamethasone—psoriasis	0.00754	0.0176	CbGbCtD
Bezafibrate—CYP3A4—Cholecalciferol—psoriasis	0.00706	0.0165	CbGbCtD
Bezafibrate—CYP3A4—Triamcinolone—psoriasis	0.00612	0.0143	CbGbCtD
Bezafibrate—CYP3A4—Mycophenolate mofetil—psoriasis	0.00612	0.0143	CbGbCtD
Bezafibrate—CYP3A4—Betamethasone—psoriasis	0.00525	0.0123	CbGbCtD
Bezafibrate—CYP3A4—Prednisolone—psoriasis	0.00518	0.0121	CbGbCtD
Bezafibrate—CYP3A4—Hydrocortisone—psoriasis	0.00492	0.0115	CbGbCtD
Bezafibrate—CYP3A4—Prednisone—psoriasis	0.0049	0.0114	CbGbCtD
Bezafibrate—CYP3A4—Cyclosporine—psoriasis	0.00464	0.0108	CbGbCtD
Bezafibrate—PPARG—dermis—psoriasis	0.00338	0.385	CbGeAlD
Bezafibrate—CYP3A4—Dexamethasone—psoriasis	0.00306	0.00713	CbGbCtD
Bezafibrate—Balsalazide—PPARG—psoriasis	0.00108	0.481	CrCbGaD
Bezafibrate—PPARG—endothelium—psoriasis	0.00103	0.118	CbGeAlD
Bezafibrate—CYP1A1—skin epidermis—psoriasis	0.000866	0.0986	CbGeAlD
Bezafibrate—PPARA—skin of body—psoriasis	0.000802	0.0913	CbGeAlD
Bezafibrate—PPARD—tendon—psoriasis	0.000716	0.0815	CbGeAlD
Bezafibrate—Indomethacin—CXCL8—psoriasis	0.000691	0.307	CrCbGaD
Bezafibrate—HMGCR—Statin Pathway—APOE—psoriasis	0.000546	0.0104	CbGpPWpGaD
Bezafibrate—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000539	0.0103	CbGpPWpGaD
Bezafibrate—HMGCR—skin of body—psoriasis	0.000534	0.0608	CbGeAlD
Bezafibrate—PPARD—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000521	0.00991	CbGpPWpGaD
Bezafibrate—PPARA—Estrogen Receptor Pathway—STAT3—psoriasis	0.000507	0.00964	CbGpPWpGaD
Bezafibrate—PPARD—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000502	0.00955	CbGpPWpGaD
Bezafibrate—PPARA—Nuclear Receptors—VDR—psoriasis	0.000502	0.00955	CbGpPWpGaD
Bezafibrate—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000501	0.00953	CbGpPWpGaD
Bezafibrate—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000488	0.00927	CbGpPWpGaD
Bezafibrate—PPARA—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000478	0.00909	CbGpPWpGaD
Bezafibrate—Indomethacin—PPARG—psoriasis	0.000477	0.212	CrCbGaD
Bezafibrate—PPARA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000474	0.00902	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000473	0.009	CbGpPWpGaD
Bezafibrate—PPARD—Nuclear Receptors—PPARG—psoriasis	0.00046	0.00874	CbGpPWpGaD
Bezafibrate—PPARG—Transcription factor regulation in adipogenesis—LEP—psoriasis	0.000446	0.00848	CbGpPWpGaD
Bezafibrate—PPARG—skin of body—psoriasis	0.000441	0.0502	CbGeAlD
Bezafibrate—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000423	0.00804	CbGpPWpGaD
Bezafibrate—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000417	0.00793	CbGpPWpGaD
Bezafibrate—HMGCR—tendon—psoriasis	0.000406	0.0462	CbGeAlD
Bezafibrate—PPARG—Differentiation of white and brown adipocyte   —LEP—psoriasis	0.000403	0.00766	CbGpPWpGaD
Bezafibrate—PPARA—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000397	0.00755	CbGpPWpGaD
Bezafibrate—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000393	0.00748	CbGpPWpGaD
Bezafibrate—HMGCR—PPARA activates gene expression—CARM1—psoriasis	0.000393	0.00747	CbGpPWpGaD
Bezafibrate—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000388	0.00737	CbGpPWpGaD
Bezafibrate—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000385	0.00731	CbGpPWpGaD
Bezafibrate—PPARA—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000383	0.00728	CbGpPWpGaD
Bezafibrate—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000382	0.00727	CbGpPWpGaD
Bezafibrate—PPARD—NRF2 pathway—TGFA—psoriasis	0.000376	0.00715	CbGpPWpGaD
Bezafibrate—PPARA—Orphan transporters—CARM1—psoriasis	0.000376	0.00715	CbGpPWpGaD
Bezafibrate—PPARD—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000363	0.00691	CbGpPWpGaD
Bezafibrate—PPARG—Nuclear Receptors—VDR—psoriasis	0.00036	0.00684	CbGpPWpGaD
Bezafibrate—PPARA—PPARA activates gene expression—CARM1—psoriasis	0.000359	0.00683	CbGpPWpGaD
Bezafibrate—PPARA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000352	0.00669	CbGpPWpGaD
Bezafibrate—PPARA—Nuclear Receptors—PPARG—psoriasis	0.00035	0.00666	CbGpPWpGaD
Bezafibrate—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000343	0.00652	CbGpPWpGaD
Bezafibrate—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000343	0.00652	CbGpPWpGaD
Bezafibrate—PPARG—tendon—psoriasis	0.000336	0.0382	CbGeAlD
Bezafibrate—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000331	0.00629	CbGpPWpGaD
Bezafibrate—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000318	0.00605	CbGpPWpGaD
Bezafibrate—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000314	0.00597	CbGpPWpGaD
Bezafibrate—PPARA—Organelle biogenesis and maintenance—CARM1—psoriasis	0.000288	0.00548	CbGpPWpGaD
Bezafibrate—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000284	0.00541	CbGpPWpGaD
Bezafibrate—PPARD—Presenilin action in Notch and Wnt signaling—JUN—psoriasis	0.00028	0.00532	CbGpPWpGaD
Bezafibrate—PPARA—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000277	0.00526	CbGpPWpGaD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000273	0.0052	CbGpPWpGaD
Bezafibrate—HMGCR—AMPK Signaling—LEP—psoriasis	0.000273	0.00519	CbGpPWpGaD
Bezafibrate—CYP1A1—skin of body—psoriasis	0.000268	0.0305	CbGeAlD
Bezafibrate—PPARD—Adipogenesis—SOCS1—psoriasis	0.000267	0.00508	CbGpPWpGaD
Bezafibrate—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000265	0.00504	CbGpPWpGaD
Bezafibrate—PPARG—PPARA activates gene expression—CARM1—psoriasis	0.000258	0.0049	CbGpPWpGaD
Bezafibrate—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000252	0.00479	CbGpPWpGaD
Bezafibrate—PPARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000252	0.00479	CbGpPWpGaD
Bezafibrate—PPARA—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000242	0.00461	CbGpPWpGaD
Bezafibrate—HMGCR—SREBP signalling—PPARG—psoriasis	0.000238	0.00452	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—TARS—psoriasis	0.000231	0.00438	CbGpPWpGaD
Bezafibrate—PPARA—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000228	0.00434	CbGpPWpGaD
Bezafibrate—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000221	0.0042	CbGpPWpGaD
Bezafibrate—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000208	0.00396	CbGpPWpGaD
Bezafibrate—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000207	0.00394	CbGpPWpGaD
Bezafibrate—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000206	0.00392	CbGpPWpGaD
Bezafibrate—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000205	0.0039	CbGpPWpGaD
Bezafibrate—PPARA—Adipogenesis—SOCS1—psoriasis	0.000204	0.00387	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000203	0.00386	CbGpPWpGaD
Bezafibrate—PPARA—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	0.000199	0.00378	CbGpPWpGaD
Bezafibrate—PPARD—Adipogenesis—LEP—psoriasis	0.000197	0.00375	CbGpPWpGaD
Bezafibrate—Pharyngitis—Cyclosporine—psoriasis	0.000197	0.00208	CcSEcCtD
Bezafibrate—Purpura—Prednisone—psoriasis	0.000197	0.00208	CcSEcCtD
Bezafibrate—Urinary tract disorder—Cyclosporine—psoriasis	0.000196	0.00207	CcSEcCtD
Bezafibrate—Hypersensitivity—Acitretin—psoriasis	0.000195	0.00206	CcSEcCtD
Bezafibrate—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000195	0.00205	CcSEcCtD
Bezafibrate—Urethral disorder—Cyclosporine—psoriasis	0.000194	0.00205	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Hydrocortisone—psoriasis	0.000194	0.00204	CcSEcCtD
Bezafibrate—Myocardial infarction—Hydrocortisone—psoriasis	0.000192	0.00203	CcSEcCtD
Bezafibrate—Pharyngitis—Mycophenolate mofetil—psoriasis	0.000192	0.00203	CcSEcCtD
Bezafibrate—Muscular weakness—Dexamethasone—psoriasis	0.000192	0.00203	CcSEcCtD
Bezafibrate—Muscular weakness—Betamethasone—psoriasis	0.000192	0.00203	CcSEcCtD
Bezafibrate—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000191	0.00202	CcSEcCtD
Bezafibrate—Urethral disorder—Mycophenolate mofetil—psoriasis	0.00019	0.002	CcSEcCtD
Bezafibrate—Rash—Calcitriol—psoriasis	0.000188	0.00198	CcSEcCtD
Bezafibrate—Dermatitis—Calcitriol—psoriasis	0.000188	0.00198	CcSEcCtD
Bezafibrate—Pruritus—Acitretin—psoriasis	0.000187	0.00198	CcSEcCtD
Bezafibrate—Pruritus—Fluocinolone Acetonide—psoriasis	0.000187	0.00197	CcSEcCtD
Bezafibrate—Headache—Calcitriol—psoriasis	0.000187	0.00197	CcSEcCtD
Bezafibrate—Dyspepsia—Hydroxyurea—psoriasis	0.000183	0.00193	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Triamcinolone—psoriasis	0.000182	0.00192	CcSEcCtD
Bezafibrate—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000182	0.00346	CbGpPWpGaD
Bezafibrate—Myalgia—Mycophenolic acid—psoriasis	0.000182	0.00192	CcSEcCtD
Bezafibrate—Diarrhoea—Acitretin—psoriasis	0.000181	0.00191	CcSEcCtD
Bezafibrate—Myocardial infarction—Triamcinolone—psoriasis	0.000181	0.00191	CcSEcCtD
Bezafibrate—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000181	0.00191	CcSEcCtD
Bezafibrate—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000181	0.00343	CbGpPWpGaD
Bezafibrate—Photosensitivity—Methotrexate—psoriasis	0.00018	0.0019	CcSEcCtD
Bezafibrate—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.00018	0.00341	CbGpPWpGaD
Bezafibrate—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000179	0.00341	CbGpPWpGaD
Bezafibrate—Constipation—Hydroxyurea—psoriasis	0.000178	0.00188	CcSEcCtD
Bezafibrate—Pain—Hydroxyurea—psoriasis	0.000178	0.00188	CcSEcCtD
Bezafibrate—Nausea—Calcitriol—psoriasis	0.000177	0.00187	CcSEcCtD
Bezafibrate—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000176	0.00336	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—TARS—psoriasis	0.000176	0.00334	CbGpPWpGaD
Bezafibrate—Alopecia—Cyclosporine—psoriasis	0.000175	0.00185	CcSEcCtD
Bezafibrate—Dizziness—Acitretin—psoriasis	0.000175	0.00185	CcSEcCtD
Bezafibrate—Dizziness—Fluocinolone Acetonide—psoriasis	0.000175	0.00184	CcSEcCtD
Bezafibrate—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000174	0.0033	CbGpPWpGaD
Bezafibrate—Infection—Mycophenolic acid—psoriasis	0.000173	0.00183	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—PPARG—psoriasis	0.000172	0.00327	CbGpPWpGaD
Bezafibrate—Renal failure acute—Methotrexate—psoriasis	0.000172	0.00181	CcSEcCtD
Bezafibrate—Alopecia—Mycophenolate mofetil—psoriasis	0.000171	0.0018	CcSEcCtD
Bezafibrate—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000171	0.0018	CcSEcCtD
Bezafibrate—Flatulence—Cyclosporine—psoriasis	0.00017	0.0018	CcSEcCtD
Bezafibrate—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000169	0.00321	CbGpPWpGaD
Bezafibrate—Muscular weakness—Prednisone—psoriasis	0.000167	0.00176	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Prednisone—psoriasis	0.000167	0.00176	CcSEcCtD
Bezafibrate—Rash—Acitretin—psoriasis	0.000167	0.00176	CcSEcCtD
Bezafibrate—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000167	0.00317	CbGpPWpGaD
Bezafibrate—Dermatitis—Acitretin—psoriasis	0.000167	0.00176	CcSEcCtD
Bezafibrate—Rash—Fluocinolone Acetonide—psoriasis	0.000167	0.00176	CcSEcCtD
Bezafibrate—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.000167	0.00317	CbGpPWpGaD
Bezafibrate—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000166	0.00176	CcSEcCtD
Bezafibrate—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000166	0.00316	CbGpPWpGaD
Bezafibrate—Muscle spasms—Cyclosporine—psoriasis	0.000166	0.00175	CcSEcCtD
Bezafibrate—Flatulence—Mycophenolate mofetil—psoriasis	0.000166	0.00175	CcSEcCtD
Bezafibrate—Headache—Acitretin—psoriasis	0.000166	0.00175	CcSEcCtD
Bezafibrate—Headache—Fluocinolone Acetonide—psoriasis	0.000165	0.00175	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Dexamethasone—psoriasis	0.000165	0.00175	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Betamethasone—psoriasis	0.000165	0.00175	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000165	0.00314	CbGpPWpGaD
Bezafibrate—Pharyngitis—Triamcinolone—psoriasis	0.000165	0.00174	CcSEcCtD
Bezafibrate—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	0.000165	0.00313	CbGpPWpGaD
Bezafibrate—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000165	0.00313	CbGpPWpGaD
Bezafibrate—Myocardial infarction—Dexamethasone—psoriasis	0.000164	0.00174	CcSEcCtD
Bezafibrate—Myocardial infarction—Betamethasone—psoriasis	0.000164	0.00174	CcSEcCtD
Bezafibrate—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000164	0.00311	CbGpPWpGaD
Bezafibrate—HMGCR—PPARA activates gene expression—PPARG—psoriasis	0.000164	0.00311	CbGpPWpGaD
Bezafibrate—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000162	0.00171	CcSEcCtD
Bezafibrate—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.00016	0.00304	CbGpPWpGaD
Bezafibrate—Anaemia—Cyclosporine—psoriasis	0.00016	0.00168	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000159	0.00168	CcSEcCtD
Bezafibrate—Insomnia—Mycophenolic acid—psoriasis	0.000158	0.00166	CcSEcCtD
Bezafibrate—Nausea—Acitretin—psoriasis	0.000157	0.00166	CcSEcCtD
Bezafibrate—Erythema—Prednisolone—psoriasis	0.000157	0.00166	CcSEcCtD
Bezafibrate—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000157	0.00299	CbGpPWpGaD
Bezafibrate—Nausea—Fluocinolone Acetonide—psoriasis	0.000157	0.00166	CcSEcCtD
Bezafibrate—Anaemia—Mycophenolate mofetil—psoriasis	0.000156	0.00164	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000154	0.00292	CbGpPWpGaD
Bezafibrate—Erythema—Hydrocortisone—psoriasis	0.000153	0.00162	CcSEcCtD
Bezafibrate—Dyspepsia—Mycophenolic acid—psoriasis	0.000153	0.00162	CcSEcCtD
Bezafibrate—Hypersensitivity—Hydroxyurea—psoriasis	0.000153	0.00162	CcSEcCtD
Bezafibrate—Erectile dysfunction—Prednisone—psoriasis	0.000151	0.00159	CcSEcCtD
Bezafibrate—PPARD—Generic Transcription Pathway—CARM1—psoriasis	0.000151	0.00287	CbGpPWpGaD
Bezafibrate—PPARA—Adipogenesis—LEP—psoriasis	0.00015	0.00286	CbGpPWpGaD
Bezafibrate—PPARA—PPARA activates gene expression—PPARG—psoriasis	0.00015	0.00284	CbGpPWpGaD
Bezafibrate—Pain—Mycophenolic acid—psoriasis	0.000149	0.00157	CcSEcCtD
Bezafibrate—Constipation—Mycophenolic acid—psoriasis	0.000149	0.00157	CcSEcCtD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—JUN—psoriasis	0.000148	0.00281	CbGpPWpGaD
Bezafibrate—Myalgia—Cyclosporine—psoriasis	0.000147	0.00155	CcSEcCtD
Bezafibrate—PPARA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000146	0.00278	CbGpPWpGaD
Bezafibrate—Liver function test abnormal—Methotrexate—psoriasis	0.000146	0.00154	CcSEcCtD
Bezafibrate—PPARG—Adipogenesis—SOCS1—psoriasis	0.000146	0.00278	CbGpPWpGaD
Bezafibrate—Erythema—Triamcinolone—psoriasis	0.000144	0.00153	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Prednisone—psoriasis	0.000144	0.00152	CcSEcCtD
Bezafibrate—Myalgia—Mycophenolate mofetil—psoriasis	0.000143	0.00151	CcSEcCtD
Bezafibrate—Myocardial infarction—Prednisone—psoriasis	0.000143	0.00151	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000143	0.00272	CbGpPWpGaD
Bezafibrate—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000143	0.00151	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000142	0.0015	CcSEcCtD
Bezafibrate—Diarrhoea—Hydroxyurea—psoriasis	0.000142	0.0015	CcSEcCtD
Bezafibrate—Infection—Cyclosporine—psoriasis	0.00014	0.00148	CcSEcCtD
Bezafibrate—Thrombocytopenia—Cyclosporine—psoriasis	0.000138	0.00146	CcSEcCtD
Bezafibrate—Abdominal pain—Mycophenolic acid—psoriasis	0.000138	0.00145	CcSEcCtD
Bezafibrate—Dizziness—Hydroxyurea—psoriasis	0.000138	0.00145	CcSEcCtD
Bezafibrate—Infection—Mycophenolate mofetil—psoriasis	0.000137	0.00144	CcSEcCtD
Bezafibrate—PPARA—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	0.000136	0.00258	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—NDUFA5—psoriasis	0.000136	0.00258	CbGpPWpGaD
Bezafibrate—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000135	0.00142	CcSEcCtD
Bezafibrate—Alopecia—Betamethasone—psoriasis	0.000133	0.0014	CcSEcCtD
Bezafibrate—Alopecia—Dexamethasone—psoriasis	0.000133	0.0014	CcSEcCtD
Bezafibrate—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000132	0.00252	CbGpPWpGaD
Bezafibrate—Rash—Hydroxyurea—psoriasis	0.000131	0.00138	CcSEcCtD
Bezafibrate—Erythema—Dexamethasone—psoriasis	0.000131	0.00138	CcSEcCtD
Bezafibrate—Erythema—Betamethasone—psoriasis	0.000131	0.00138	CcSEcCtD
Bezafibrate—Dermatitis—Hydroxyurea—psoriasis	0.000131	0.00138	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—PPARG—psoriasis	0.000131	0.00249	CbGpPWpGaD
Bezafibrate—Myalgia—Hydrocortisone—psoriasis	0.000131	0.00138	CcSEcCtD
Bezafibrate—Headache—Hydroxyurea—psoriasis	0.00013	0.00138	CcSEcCtD
Bezafibrate—Pancytopenia—Methotrexate—psoriasis	0.00013	0.00137	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000128	0.00136	CcSEcCtD
Bezafibrate—Insomnia—Cyclosporine—psoriasis	0.000127	0.00135	CcSEcCtD
Bezafibrate—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000127	0.00242	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000127	0.00241	CbGpPWpGaD
Bezafibrate—Erectile dysfunction—Methotrexate—psoriasis	0.000126	0.00133	CcSEcCtD
Bezafibrate—PPARG—Gene Expression—TARS—psoriasis	0.000126	0.00239	CbGpPWpGaD
Bezafibrate—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000125	0.00132	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Methotrexate—psoriasis	0.000125	0.00132	CcSEcCtD
Bezafibrate—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000124	0.00237	CbGpPWpGaD
Bezafibrate—Infection—Hydrocortisone—psoriasis	0.000124	0.00131	CcSEcCtD
Bezafibrate—Insomnia—Mycophenolate mofetil—psoriasis	0.000124	0.00131	CcSEcCtD
Bezafibrate—Dyspepsia—Cyclosporine—psoriasis	0.000124	0.00131	CcSEcCtD
Bezafibrate—Nausea—Hydroxyurea—psoriasis	0.000124	0.0013	CcSEcCtD
Bezafibrate—Pruritus—Mycophenolic acid—psoriasis	0.000123	0.0013	CcSEcCtD
Bezafibrate—Myalgia—Triamcinolone—psoriasis	0.000123	0.0013	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000121	0.00128	CcSEcCtD
Bezafibrate—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000121	0.00128	CcSEcCtD
Bezafibrate—Pain—Cyclosporine—psoriasis	0.00012	0.00127	CcSEcCtD
Bezafibrate—Constipation—Cyclosporine—psoriasis	0.00012	0.00127	CcSEcCtD
Bezafibrate—Diarrhoea—Mycophenolic acid—psoriasis	0.000119	0.00126	CcSEcCtD
Bezafibrate—Pain—Mycophenolate mofetil—psoriasis	0.000118	0.00124	CcSEcCtD
Bezafibrate—Constipation—Mycophenolate mofetil—psoriasis	0.000118	0.00124	CcSEcCtD
Bezafibrate—Infection—Triamcinolone—psoriasis	0.000117	0.00124	CcSEcCtD
Bezafibrate—Insomnia—Prednisolone—psoriasis	0.000116	0.00122	CcSEcCtD
Bezafibrate—Alopecia—Prednisone—psoriasis	0.000116	0.00122	CcSEcCtD
Bezafibrate—PPARD—Metabolism—CYP2S1—psoriasis	0.000116	0.0022	CbGpPWpGaD
Bezafibrate—Gastrointestinal pain—Cyclosporine—psoriasis	0.000115	0.00122	CcSEcCtD
Bezafibrate—Dizziness—Mycophenolic acid—psoriasis	0.000115	0.00122	CcSEcCtD
Bezafibrate—PPARA—Generic Transcription Pathway—CARM1—psoriasis	0.000115	0.00218	CbGpPWpGaD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	0.000114	0.00218	CbGpPWpGaD
Bezafibrate—Erythema—Prednisone—psoriasis	0.000114	0.00121	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000114	0.0012	CcSEcCtD
Bezafibrate—Insomnia—Hydrocortisone—psoriasis	0.000113	0.0012	CcSEcCtD
Bezafibrate—HMGCR—Metabolism—NDUFA5—psoriasis	0.000113	0.00215	CbGpPWpGaD
Bezafibrate—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000112	0.00119	CcSEcCtD
Bezafibrate—Urticaria—Cyclosporine—psoriasis	0.000112	0.00118	CcSEcCtD
Bezafibrate—Myalgia—Dexamethasone—psoriasis	0.000112	0.00118	CcSEcCtD
Bezafibrate—Myalgia—Betamethasone—psoriasis	0.000112	0.00118	CcSEcCtD
Bezafibrate—Abdominal pain—Cyclosporine—psoriasis	0.000111	0.00118	CcSEcCtD
Bezafibrate—HMGCR—AMPK Signaling—TP53—psoriasis	0.000111	0.00212	CbGpPWpGaD
Bezafibrate—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.00011	0.0021	CbGpPWpGaD
Bezafibrate—Dyspepsia—Hydrocortisone—psoriasis	0.00011	0.00116	CcSEcCtD
Bezafibrate—Rash—Mycophenolic acid—psoriasis	0.00011	0.00116	CcSEcCtD
Bezafibrate—Dermatitis—Mycophenolic acid—psoriasis	0.00011	0.00116	CcSEcCtD
Bezafibrate—Pain—Prednisolone—psoriasis	0.00011	0.00116	CcSEcCtD
Bezafibrate—Urticaria—Mycophenolate mofetil—psoriasis	0.000109	0.00115	CcSEcCtD
Bezafibrate—Headache—Mycophenolic acid—psoriasis	0.000109	0.00115	CcSEcCtD
Bezafibrate—Pharyngitis—Methotrexate—psoriasis	0.000109	0.00115	CcSEcCtD
Bezafibrate—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000109	0.00115	CcSEcCtD
Bezafibrate—Urinary tract disorder—Methotrexate—psoriasis	0.000108	0.00114	CcSEcCtD
Bezafibrate—PPARA—Developmental Biology—CARM1—psoriasis	0.000108	0.00206	CbGpPWpGaD
Bezafibrate—PPARG—Adipogenesis—LEP—psoriasis	0.000108	0.00205	CbGpPWpGaD
Bezafibrate—Urethral disorder—Methotrexate—psoriasis	0.000107	0.00113	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000107	0.00113	CcSEcCtD
Bezafibrate—Pain—Hydrocortisone—psoriasis	0.000107	0.00113	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	0.000107	0.00203	CbGpPWpGaD
Bezafibrate—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	0.000107	0.00203	CbGpPWpGaD
Bezafibrate—Insomnia—Triamcinolone—psoriasis	0.000107	0.00113	CcSEcCtD
Bezafibrate—Infection—Betamethasone—psoriasis	0.000106	0.00112	CcSEcCtD
Bezafibrate—Infection—Dexamethasone—psoriasis	0.000106	0.00112	CcSEcCtD
Bezafibrate—PPARA—Circadian rythm related genes—LEP—psoriasis	0.000106	0.00202	CbGpPWpGaD
Bezafibrate—PPARA—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	0.000106	0.00201	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000106	0.00201	CbGpPWpGaD
Bezafibrate—Anaemia—Prednisone—psoriasis	0.000106	0.00111	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—STAT3—psoriasis	0.000105	0.002	CbGpPWpGaD
Bezafibrate—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	0.000105	0.002	CbGpPWpGaD
Bezafibrate—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000105	0.002	CbGpPWpGaD
Bezafibrate—Thrombocytopenia—Dexamethasone—psoriasis	0.000105	0.00111	CcSEcCtD
Bezafibrate—Thrombocytopenia—Betamethasone—psoriasis	0.000105	0.00111	CcSEcCtD
Bezafibrate—Hypersensitivity—Cyclosporine—psoriasis	0.000104	0.0011	CcSEcCtD
Bezafibrate—Dyspepsia—Triamcinolone—psoriasis	0.000104	0.0011	CcSEcCtD
Bezafibrate—Erythema multiforme—Methotrexate—psoriasis	0.000104	0.00109	CcSEcCtD
Bezafibrate—PPARA—Metabolism—NDUFA5—psoriasis	0.000104	0.00197	CbGpPWpGaD
Bezafibrate—Nausea—Mycophenolic acid—psoriasis	0.000103	0.00109	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000102	0.00108	CcSEcCtD
Bezafibrate—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000102	0.00194	CbGpPWpGaD
Bezafibrate—Urticaria—Prednisolone—psoriasis	0.000102	0.00108	CcSEcCtD
Bezafibrate—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000101	0.00107	CcSEcCtD
Bezafibrate—PPARA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000101	0.00192	CbGpPWpGaD
Bezafibrate—Pain—Triamcinolone—psoriasis	0.000101	0.00106	CcSEcCtD
Bezafibrate—Pruritus—Cyclosporine—psoriasis	9.97e-05	0.00105	CcSEcCtD
Bezafibrate—Urticaria—Hydrocortisone—psoriasis	9.95e-05	0.00105	CcSEcCtD
Bezafibrate—Abdominal pain—Hydrocortisone—psoriasis	9.9e-05	0.00105	CcSEcCtD
Bezafibrate—PPARA—Circadian rythm related genes—NOS2—psoriasis	9.88e-05	0.00188	CbGpPWpGaD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—psoriasis	9.77e-05	0.00186	CbGpPWpGaD
Bezafibrate—Musculoskeletal discomfort—Dexamethasone—psoriasis	9.75e-05	0.00103	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Betamethasone—psoriasis	9.75e-05	0.00103	CcSEcCtD
Bezafibrate—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	9.74e-05	0.00185	CbGpPWpGaD
Bezafibrate—Pruritus—Mycophenolate mofetil—psoriasis	9.72e-05	0.00103	CcSEcCtD
Bezafibrate—Myalgia—Prednisone—psoriasis	9.72e-05	0.00103	CcSEcCtD
Bezafibrate—Alopecia—Methotrexate—psoriasis	9.69e-05	0.00102	CcSEcCtD
Bezafibrate—Insomnia—Betamethasone—psoriasis	9.68e-05	0.00102	CcSEcCtD
Bezafibrate—Insomnia—Dexamethasone—psoriasis	9.68e-05	0.00102	CcSEcCtD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.65e-05	0.00184	CbGpPWpGaD
Bezafibrate—Diarrhoea—Cyclosporine—psoriasis	9.64e-05	0.00102	CcSEcCtD
Bezafibrate—HMGCR—Metabolism—CYP2S1—psoriasis	9.62e-05	0.00183	CbGpPWpGaD
Bezafibrate—PPARA—Transmembrane transport of small molecules—CP—psoriasis	9.62e-05	0.00183	CbGpPWpGaD
Bezafibrate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.56e-05	0.00182	CbGpPWpGaD
Bezafibrate—Erythema—Methotrexate—psoriasis	9.54e-05	0.00101	CcSEcCtD
Bezafibrate—Hypersensitivity—Prednisolone—psoriasis	9.45e-05	0.000997	CcSEcCtD
Bezafibrate—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	9.44e-05	0.0018	CbGpPWpGaD
Bezafibrate—Dyspepsia—Dexamethasone—psoriasis	9.42e-05	0.000994	CcSEcCtD
Bezafibrate—Dyspepsia—Betamethasone—psoriasis	9.42e-05	0.000994	CcSEcCtD
Bezafibrate—Diarrhoea—Mycophenolate mofetil—psoriasis	9.4e-05	0.000993	CcSEcCtD
Bezafibrate—Urticaria—Triamcinolone—psoriasis	9.37e-05	0.000989	CcSEcCtD
Bezafibrate—Dizziness—Cyclosporine—psoriasis	9.32e-05	0.000984	CcSEcCtD
Bezafibrate—Infection—Prednisone—psoriasis	9.26e-05	0.000977	CcSEcCtD
Bezafibrate—PPARA—Circadian rythm related genes—PPARG—psoriasis	9.24e-05	0.00176	CbGpPWpGaD
Bezafibrate—Hypersensitivity—Hydrocortisone—psoriasis	9.23e-05	0.000974	CcSEcCtD
Bezafibrate—PPARA—Transmembrane transport of small molecules—CARM1—psoriasis	9.18e-05	0.00175	CbGpPWpGaD
Bezafibrate—Pain—Dexamethasone—psoriasis	9.15e-05	0.000966	CcSEcCtD
Bezafibrate—Pain—Betamethasone—psoriasis	9.15e-05	0.000966	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—TNF—psoriasis	9.12e-05	0.00174	CbGpPWpGaD
Bezafibrate—Dizziness—Mycophenolate mofetil—psoriasis	9.09e-05	0.00096	CcSEcCtD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—JUN—psoriasis	9e-05	0.00171	CbGpPWpGaD
Bezafibrate—PPARD—Generic Transcription Pathway—VDR—psoriasis	9e-05	0.00171	CbGpPWpGaD
Bezafibrate—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.96e-05	0.0017	CbGpPWpGaD
Bezafibrate—Rash—Cyclosporine—psoriasis	8.88e-05	0.000938	CcSEcCtD
Bezafibrate—Dermatitis—Cyclosporine—psoriasis	8.88e-05	0.000937	CcSEcCtD
Bezafibrate—Pruritus—Hydrocortisone—psoriasis	8.86e-05	0.000935	CcSEcCtD
Bezafibrate—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.83e-05	0.00168	CbGpPWpGaD
Bezafibrate—Headache—Cyclosporine—psoriasis	8.83e-05	0.000932	CcSEcCtD
Bezafibrate—Anaemia—Methotrexate—psoriasis	8.82e-05	0.000931	CcSEcCtD
Bezafibrate—PPARA—Metabolism—CYP2S1—psoriasis	8.8e-05	0.00167	CbGpPWpGaD
Bezafibrate—Gastrointestinal pain—Dexamethasone—psoriasis	8.75e-05	0.000924	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Betamethasone—psoriasis	8.75e-05	0.000924	CcSEcCtD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.72e-05	0.00166	CbGpPWpGaD
Bezafibrate—Hypersensitivity—Triamcinolone—psoriasis	8.69e-05	0.000917	CcSEcCtD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	8.67e-05	0.00165	CbGpPWpGaD
Bezafibrate—Rash—Mycophenolate mofetil—psoriasis	8.67e-05	0.000915	CcSEcCtD
Bezafibrate—Dermatitis—Mycophenolate mofetil—psoriasis	8.66e-05	0.000914	CcSEcCtD
Bezafibrate—Headache—Mycophenolate mofetil—psoriasis	8.61e-05	0.000909	CcSEcCtD
Bezafibrate—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	8.57e-05	0.00163	CbGpPWpGaD
Bezafibrate—Diarrhoea—Hydrocortisone—psoriasis	8.57e-05	0.000904	CcSEcCtD
Bezafibrate—Urticaria—Dexamethasone—psoriasis	8.5e-05	0.000897	CcSEcCtD
Bezafibrate—Urticaria—Betamethasone—psoriasis	8.5e-05	0.000897	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Prednisone—psoriasis	8.49e-05	0.000896	CcSEcCtD
Bezafibrate—Dizziness—Prednisolone—psoriasis	8.48e-05	0.000895	CcSEcCtD
Bezafibrate—Abdominal pain—Betamethasone—psoriasis	8.46e-05	0.000893	CcSEcCtD
Bezafibrate—Abdominal pain—Dexamethasone—psoriasis	8.46e-05	0.000893	CcSEcCtD
Bezafibrate—Insomnia—Prednisone—psoriasis	8.43e-05	0.00089	CcSEcCtD
Bezafibrate—Nausea—Cyclosporine—psoriasis	8.37e-05	0.000884	CcSEcCtD
Bezafibrate—Pruritus—Triamcinolone—psoriasis	8.34e-05	0.000881	CcSEcCtD
Bezafibrate—Dizziness—Hydrocortisone—psoriasis	8.28e-05	0.000874	CcSEcCtD
Bezafibrate—PPARG—Generic Transcription Pathway—CARM1—psoriasis	8.23e-05	0.00156	CbGpPWpGaD
Bezafibrate—Dyspepsia—Prednisone—psoriasis	8.2e-05	0.000866	CcSEcCtD
Bezafibrate—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	8.17e-05	0.00155	CbGpPWpGaD
Bezafibrate—Nausea—Mycophenolate mofetil—psoriasis	8.16e-05	0.000862	CcSEcCtD
Bezafibrate—Myalgia—Methotrexate—psoriasis	8.12e-05	0.000857	CcSEcCtD
Bezafibrate—Rash—Prednisolone—psoriasis	8.08e-05	0.000853	CcSEcCtD
Bezafibrate—Dermatitis—Prednisolone—psoriasis	8.08e-05	0.000853	CcSEcCtD
Bezafibrate—Headache—Prednisolone—psoriasis	8.03e-05	0.000848	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—STAT3—psoriasis	8.03e-05	0.00153	CbGpPWpGaD
Bezafibrate—Constipation—Prednisone—psoriasis	7.97e-05	0.000841	CcSEcCtD
Bezafibrate—Rash—Hydrocortisone—psoriasis	7.9e-05	0.000833	CcSEcCtD
Bezafibrate—Dermatitis—Hydrocortisone—psoriasis	7.89e-05	0.000833	CcSEcCtD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	7.87e-05	0.0015	CbGpPWpGaD
Bezafibrate—Headache—Hydrocortisone—psoriasis	7.84e-05	0.000828	CcSEcCtD
Bezafibrate—Dizziness—Triamcinolone—psoriasis	7.8e-05	0.000823	CcSEcCtD
Bezafibrate—PPARG—Developmental Biology—CARM1—psoriasis	7.74e-05	0.00147	CbGpPWpGaD
Bezafibrate—Infection—Methotrexate—psoriasis	7.74e-05	0.000817	CcSEcCtD
Bezafibrate—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.73e-05	0.00147	CbGpPWpGaD
Bezafibrate—Thrombocytopenia—Methotrexate—psoriasis	7.62e-05	0.000805	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Prednisone—psoriasis	7.62e-05	0.000804	CcSEcCtD
Bezafibrate—Nausea—Prednisolone—psoriasis	7.62e-05	0.000804	CcSEcCtD
Bezafibrate—PPARG—Circadian rythm related genes—LEP—psoriasis	7.6e-05	0.00145	CbGpPWpGaD
Bezafibrate—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	7.57e-05	0.00144	CbGpPWpGaD
Bezafibrate—Pruritus—Betamethasone—psoriasis	7.57e-05	0.000799	CcSEcCtD
Bezafibrate—Pruritus—Dexamethasone—psoriasis	7.57e-05	0.000799	CcSEcCtD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.54e-05	0.00143	CbGpPWpGaD
Bezafibrate—Nausea—Hydrocortisone—psoriasis	7.44e-05	0.000785	CcSEcCtD
Bezafibrate—Rash—Triamcinolone—psoriasis	7.43e-05	0.000785	CcSEcCtD
Bezafibrate—Dermatitis—Triamcinolone—psoriasis	7.43e-05	0.000784	CcSEcCtD
Bezafibrate—PPARG—Metabolism—NDUFA5—psoriasis	7.42e-05	0.00141	CbGpPWpGaD
Bezafibrate—Urticaria—Prednisone—psoriasis	7.4e-05	0.000781	CcSEcCtD
Bezafibrate—Headache—Triamcinolone—psoriasis	7.39e-05	0.00078	CcSEcCtD
Bezafibrate—Abdominal pain—Prednisone—psoriasis	7.37e-05	0.000778	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—IL6—psoriasis	7.36e-05	0.0014	CbGpPWpGaD
Bezafibrate—Diarrhoea—Dexamethasone—psoriasis	7.32e-05	0.000773	CcSEcCtD
Bezafibrate—Diarrhoea—Betamethasone—psoriasis	7.32e-05	0.000773	CcSEcCtD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.26e-05	0.00138	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—CARM1—psoriasis	7.26e-05	0.00138	CbGpPWpGaD
Bezafibrate—Musculoskeletal discomfort—Methotrexate—psoriasis	7.09e-05	0.000749	CcSEcCtD
Bezafibrate—PPARG—Circadian rythm related genes—NOS2—psoriasis	7.08e-05	0.00135	CbGpPWpGaD
Bezafibrate—Dizziness—Betamethasone—psoriasis	7.07e-05	0.000747	CcSEcCtD
Bezafibrate—Dizziness—Dexamethasone—psoriasis	7.07e-05	0.000747	CcSEcCtD
Bezafibrate—Insomnia—Methotrexate—psoriasis	7.04e-05	0.000743	CcSEcCtD
Bezafibrate—Nausea—Triamcinolone—psoriasis	7e-05	0.000739	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—TNF—psoriasis	6.95e-05	0.00132	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.92e-05	0.00132	CbGpPWpGaD
Bezafibrate—Hypersensitivity—Prednisone—psoriasis	6.86e-05	0.000725	CcSEcCtD
Bezafibrate—PPARA—Generic Transcription Pathway—VDR—psoriasis	6.86e-05	0.0013	CbGpPWpGaD
Bezafibrate—Dyspepsia—Methotrexate—psoriasis	6.85e-05	0.000724	CcSEcCtD
Bezafibrate—Rash—Dexamethasone—psoriasis	6.75e-05	0.000712	CcSEcCtD
Bezafibrate—Rash—Betamethasone—psoriasis	6.75e-05	0.000712	CcSEcCtD
Bezafibrate—Dermatitis—Dexamethasone—psoriasis	6.74e-05	0.000711	CcSEcCtD
Bezafibrate—Dermatitis—Betamethasone—psoriasis	6.74e-05	0.000711	CcSEcCtD
Bezafibrate—Headache—Betamethasone—psoriasis	6.7e-05	0.000708	CcSEcCtD
Bezafibrate—Headache—Dexamethasone—psoriasis	6.7e-05	0.000708	CcSEcCtD
Bezafibrate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.66e-05	0.00127	CbGpPWpGaD
Bezafibrate—Pain—Methotrexate—psoriasis	6.66e-05	0.000703	CcSEcCtD
Bezafibrate—Pruritus—Prednisone—psoriasis	6.59e-05	0.000696	CcSEcCtD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.59e-05	0.00125	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—JUN—psoriasis	6.55e-05	0.00125	CbGpPWpGaD
Bezafibrate—Diarrhoea—Prednisone—psoriasis	6.37e-05	0.000673	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Methotrexate—psoriasis	6.37e-05	0.000672	CcSEcCtD
Bezafibrate—Nausea—Betamethasone—psoriasis	6.35e-05	0.000671	CcSEcCtD
Bezafibrate—Nausea—Dexamethasone—psoriasis	6.35e-05	0.000671	CcSEcCtD
Bezafibrate—PPARG—Metabolism—CYP2S1—psoriasis	6.31e-05	0.0012	CbGpPWpGaD
Bezafibrate—PPARD—Generic Transcription Pathway—PPARG—psoriasis	6.27e-05	0.00119	CbGpPWpGaD
Bezafibrate—Urticaria—Methotrexate—psoriasis	6.19e-05	0.000653	CcSEcCtD
Bezafibrate—Dizziness—Prednisone—psoriasis	6.16e-05	0.00065	CcSEcCtD
Bezafibrate—Abdominal pain—Methotrexate—psoriasis	6.16e-05	0.00065	CcSEcCtD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.05e-05	0.00115	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—TP53—psoriasis	5.94e-05	0.00113	CbGpPWpGaD
Bezafibrate—Rash—Prednisone—psoriasis	5.87e-05	0.00062	CcSEcCtD
Bezafibrate—Dermatitis—Prednisone—psoriasis	5.87e-05	0.00062	CcSEcCtD
Bezafibrate—SLCO1B1—Metabolism—NDUFA5—psoriasis	5.84e-05	0.00111	CbGpPWpGaD
Bezafibrate—Headache—Prednisone—psoriasis	5.84e-05	0.000616	CcSEcCtD
Bezafibrate—PPARG—Adipogenesis—STAT3—psoriasis	5.76e-05	0.00109	CbGpPWpGaD
Bezafibrate—Hypersensitivity—Methotrexate—psoriasis	5.74e-05	0.000606	CcSEcCtD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.64e-05	0.00107	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.64e-05	0.00107	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—CARM1—psoriasis	5.64e-05	0.00107	CbGpPWpGaD
Bezafibrate—PPARA—Adipogenesis—IL6—psoriasis	5.61e-05	0.00107	CbGpPWpGaD
Bezafibrate—Nausea—Prednisone—psoriasis	5.53e-05	0.000584	CcSEcCtD
Bezafibrate—PPARA—Gene Expression—CARM1—psoriasis	5.53e-05	0.00105	CbGpPWpGaD
Bezafibrate—Pruritus—Methotrexate—psoriasis	5.51e-05	0.000582	CcSEcCtD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.45e-05	0.00104	CbGpPWpGaD
Bezafibrate—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	5.43e-05	0.00103	CbGpPWpGaD
Bezafibrate—Diarrhoea—Methotrexate—psoriasis	5.33e-05	0.000562	CcSEcCtD
Bezafibrate—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	5.29e-05	0.00101	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.27e-05	0.001	CbGpPWpGaD
Bezafibrate—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.18e-05	0.000985	CbGpPWpGaD
Bezafibrate—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	5.18e-05	0.000985	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—LEP—psoriasis	5.16e-05	0.000982	CbGpPWpGaD
Bezafibrate—Dizziness—Methotrexate—psoriasis	5.15e-05	0.000544	CcSEcCtD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.04e-05	0.000959	CbGpPWpGaD
Bezafibrate—PPARG—Adipogenesis—TNF—psoriasis	4.98e-05	0.000947	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—CYP2S1—psoriasis	4.97e-05	0.000945	CbGpPWpGaD
Bezafibrate—PPARG—Generic Transcription Pathway—VDR—psoriasis	4.91e-05	0.000934	CbGpPWpGaD
Bezafibrate—Rash—Methotrexate—psoriasis	4.91e-05	0.000518	CcSEcCtD
Bezafibrate—Dermatitis—Methotrexate—psoriasis	4.91e-05	0.000518	CcSEcCtD
Bezafibrate—Headache—Methotrexate—psoriasis	4.88e-05	0.000515	CcSEcCtD
Bezafibrate—PPARA—Generic Transcription Pathway—PPARG—psoriasis	4.78e-05	0.000909	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—CARM1—psoriasis	4.7e-05	0.000894	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—JUN—psoriasis	4.69e-05	0.000893	CbGpPWpGaD
Bezafibrate—Nausea—Methotrexate—psoriasis	4.63e-05	0.000488	CcSEcCtD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.61e-05	0.000877	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—PPARG—psoriasis	4.5e-05	0.000855	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.39e-05	0.000835	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—VDR—psoriasis	4.33e-05	0.000824	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—TP53—psoriasis	4.32e-05	0.000822	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—CARM1—psoriasis	4.3e-05	0.000817	CbGpPWpGaD
Bezafibrate—PPARG—Adipogenesis—IL6—psoriasis	4.02e-05	0.000764	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.02e-05	0.000764	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—CARM1—psoriasis	3.96e-05	0.000753	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—IL6—psoriasis	3.96e-05	0.000753	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—TYK2—psoriasis	3.94e-05	0.00075	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—LEP—psoriasis	3.7e-05	0.000704	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—NDUFA5—psoriasis	3.66e-05	0.000696	CbGpPWpGaD
Bezafibrate—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.57e-05	0.000679	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—CAT—psoriasis	3.47e-05	0.00066	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.41e-05	0.000649	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—NDUFA5—psoriasis	3.36e-05	0.000638	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.31e-05	0.000629	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—VDR—psoriasis	3.3e-05	0.000628	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.13e-05	0.000595	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—CYP2S1—psoriasis	3.11e-05	0.000592	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—TP53—psoriasis	3.1e-05	0.000589	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—CARM1—psoriasis	3.08e-05	0.000586	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—NFKB1—psoriasis	3.07e-05	0.000584	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—PPARG—psoriasis	3.02e-05	0.000574	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—CAT—psoriasis	2.89e-05	0.00055	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—CYP2S1—psoriasis	2.85e-05	0.000543	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—IL6—psoriasis	2.84e-05	0.000539	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—TYK2—psoriasis	2.82e-05	0.000537	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—VEGFA—psoriasis	2.79e-05	0.00053	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—STAT3—psoriasis	2.76e-05	0.000525	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—APOE—psoriasis	2.7e-05	0.000513	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—CAT—psoriasis	2.64e-05	0.000503	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.6e-05	0.000495	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—CARM1—psoriasis	2.43e-05	0.000461	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—TNF—psoriasis	2.39e-05	0.000454	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—VDR—psoriasis	2.37e-05	0.00045	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—PPARG—psoriasis	2.35e-05	0.000447	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—PPARG—psoriasis	2.3e-05	0.000438	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.27e-05	0.000431	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—APOE—psoriasis	2.25e-05	0.000427	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—NFKB1—psoriasis	2.2e-05	0.000419	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—APOE—psoriasis	2.05e-05	0.000391	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—VEGFA—psoriasis	2e-05	0.00038	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—STAT3—psoriasis	1.98e-05	0.000376	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—PPARG—psoriasis	1.96e-05	0.000372	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—IL6—psoriasis	1.93e-05	0.000367	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—CAT—psoriasis	1.89e-05	0.00036	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—NDUFA5—psoriasis	1.8e-05	0.000343	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—PPARG—psoriasis	1.79e-05	0.00034	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—TNF—psoriasis	1.71e-05	0.000326	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.63e-05	0.00031	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—CYP2S1—psoriasis	1.53e-05	0.000291	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—CARM1—psoriasis	1.52e-05	0.000289	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.5e-05	0.000284	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—CAT—psoriasis	1.49e-05	0.000284	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—APOE—psoriasis	1.47e-05	0.00028	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.42e-05	0.00027	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—CARM1—psoriasis	1.39e-05	0.000265	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—IL6—psoriasis	1.38e-05	0.000263	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.3e-05	0.000248	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—APOE—psoriasis	1.16e-05	0.00022	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PPARG—psoriasis	1.01e-05	0.000192	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—CAT—psoriasis	9.35e-06	0.000178	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—CAT—psoriasis	8.57e-06	0.000163	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—CARM1—psoriasis	7.48e-06	0.000142	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—APOE—psoriasis	7.27e-06	0.000138	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—APOE—psoriasis	6.66e-06	0.000127	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PPARG—psoriasis	6.33e-06	0.00012	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PPARG—psoriasis	5.8e-06	0.00011	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—CAT—psoriasis	4.6e-06	8.75e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—APOE—psoriasis	3.58e-06	6.8e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PPARG—psoriasis	3.11e-06	5.92e-05	CbGpPWpGaD
